Screening for obstructive sleep apnoea in post‐treatment cancer patients
Abstract Background and aims For cancer patients, comorbid obstructive sleep apnea (OSA) poses additional risk to their surgical/anaesthetic outcomes, quality of life, and survival. However, OSA screening is not well‐established in oncology settings. We tested two screening tools (STOP‐Bang question...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1740 |
| _version_ | 1797867124959477760 |
|---|---|
| author | Harini Subramanian Veronika Fuchsova Elisabeth Elder Alison Brand Julie Howle Anna DeFazio Graham J. Mann Terence Amis Kristina Kairaitis |
| author_facet | Harini Subramanian Veronika Fuchsova Elisabeth Elder Alison Brand Julie Howle Anna DeFazio Graham J. Mann Terence Amis Kristina Kairaitis |
| author_sort | Harini Subramanian |
| collection | DOAJ |
| description | Abstract Background and aims For cancer patients, comorbid obstructive sleep apnea (OSA) poses additional risk to their surgical/anaesthetic outcomes, quality of life, and survival. However, OSA screening is not well‐established in oncology settings. We tested two screening tools (STOP‐Bang questionnaire [SBQ] and the at‐home monitoring device, ApneaLink™Air), for predicting polysomnography (PSG) confirmed OSA in post‐treatment cancer patients. Methods Breast (n = 56), endometrial (n = 37) and melanoma patients (n = 50) were recruited from follow‐up clinics at Westmead Hospital (Sydney, Australia). All underwent overnight PSG, 137 completed SBQ, and 99 completed ApneaLink™Air. Positive (PPV) and negative (NPV) predictive values for PSG‐determined moderate‐to‐severe OSA and severe OSA, were calculated using an SBQ threshold ≥3 au and ApneaLink™Air apnoea‐hypopnea index thresholds of ≥10, ≥15 and ≥30 events/h. Results Both SBQ and ApneaLink™Air had high NPVs (92.7% and 85.2%–95.6% respectively) for severe OSA, but NPVs were lower for moderate‐to‐severe OSA (69.1% and 59.1%–75.5%, respectively). PPV for both tools were relatively low (all <73%). Combining both tools did not improve screening performance. Conclusions These screening tools may help identify cancer patients without severe OSA, but both are limited in identifying those with moderate‐to‐severe or severe OSA. PSG remains optimal for adequately identifying and managing comorbid OSA in cancer patients. |
| first_indexed | 2024-04-09T23:36:22Z |
| format | Article |
| id | doaj.art-95406cde5b55473e9b675e962dc9a5e4 |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-04-09T23:36:22Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-95406cde5b55473e9b675e962dc9a5e42023-03-20T11:07:47ZengWileyCancer Reports2573-83482023-03-0163n/an/a10.1002/cnr2.1740Screening for obstructive sleep apnoea in post‐treatment cancer patientsHarini Subramanian0Veronika Fuchsova1Elisabeth Elder2Alison Brand3Julie Howle4Anna DeFazio5Graham J. Mann6Terence Amis7Kristina Kairaitis8Ludwig Engel Centre for Respiratory Research The Westmead Institute for Medical Research Westmead AustraliaLudwig Engel Centre for Respiratory Research The Westmead Institute for Medical Research Westmead AustraliaWestmead Clinical School, Faculty of Medicine and Health The University of Sydney Westmead AustraliaWestmead Clinical School, Faculty of Medicine and Health The University of Sydney Westmead AustraliaWestmead Clinical School, Faculty of Medicine and Health The University of Sydney Westmead AustraliaDepartment of Gynaecological Oncology Westmead Hospital Westmead AustraliaMelanoma Institute Australia The University of Sydney Camperdown AustraliaLudwig Engel Centre for Respiratory Research The Westmead Institute for Medical Research Westmead AustraliaLudwig Engel Centre for Respiratory Research The Westmead Institute for Medical Research Westmead AustraliaAbstract Background and aims For cancer patients, comorbid obstructive sleep apnea (OSA) poses additional risk to their surgical/anaesthetic outcomes, quality of life, and survival. However, OSA screening is not well‐established in oncology settings. We tested two screening tools (STOP‐Bang questionnaire [SBQ] and the at‐home monitoring device, ApneaLink™Air), for predicting polysomnography (PSG) confirmed OSA in post‐treatment cancer patients. Methods Breast (n = 56), endometrial (n = 37) and melanoma patients (n = 50) were recruited from follow‐up clinics at Westmead Hospital (Sydney, Australia). All underwent overnight PSG, 137 completed SBQ, and 99 completed ApneaLink™Air. Positive (PPV) and negative (NPV) predictive values for PSG‐determined moderate‐to‐severe OSA and severe OSA, were calculated using an SBQ threshold ≥3 au and ApneaLink™Air apnoea‐hypopnea index thresholds of ≥10, ≥15 and ≥30 events/h. Results Both SBQ and ApneaLink™Air had high NPVs (92.7% and 85.2%–95.6% respectively) for severe OSA, but NPVs were lower for moderate‐to‐severe OSA (69.1% and 59.1%–75.5%, respectively). PPV for both tools were relatively low (all <73%). Combining both tools did not improve screening performance. Conclusions These screening tools may help identify cancer patients without severe OSA, but both are limited in identifying those with moderate‐to‐severe or severe OSA. PSG remains optimal for adequately identifying and managing comorbid OSA in cancer patients.https://doi.org/10.1002/cnr2.1740breast cancercancer outcomesendometrial cancermelanomascreeningsleep apnea |
| spellingShingle | Harini Subramanian Veronika Fuchsova Elisabeth Elder Alison Brand Julie Howle Anna DeFazio Graham J. Mann Terence Amis Kristina Kairaitis Screening for obstructive sleep apnoea in post‐treatment cancer patients Cancer Reports breast cancer cancer outcomes endometrial cancer melanoma screening sleep apnea |
| title | Screening for obstructive sleep apnoea in post‐treatment cancer patients |
| title_full | Screening for obstructive sleep apnoea in post‐treatment cancer patients |
| title_fullStr | Screening for obstructive sleep apnoea in post‐treatment cancer patients |
| title_full_unstemmed | Screening for obstructive sleep apnoea in post‐treatment cancer patients |
| title_short | Screening for obstructive sleep apnoea in post‐treatment cancer patients |
| title_sort | screening for obstructive sleep apnoea in post treatment cancer patients |
| topic | breast cancer cancer outcomes endometrial cancer melanoma screening sleep apnea |
| url | https://doi.org/10.1002/cnr2.1740 |
| work_keys_str_mv | AT harinisubramanian screeningforobstructivesleepapnoeainposttreatmentcancerpatients AT veronikafuchsova screeningforobstructivesleepapnoeainposttreatmentcancerpatients AT elisabethelder screeningforobstructivesleepapnoeainposttreatmentcancerpatients AT alisonbrand screeningforobstructivesleepapnoeainposttreatmentcancerpatients AT juliehowle screeningforobstructivesleepapnoeainposttreatmentcancerpatients AT annadefazio screeningforobstructivesleepapnoeainposttreatmentcancerpatients AT grahamjmann screeningforobstructivesleepapnoeainposttreatmentcancerpatients AT terenceamis screeningforobstructivesleepapnoeainposttreatmentcancerpatients AT kristinakairaitis screeningforobstructivesleepapnoeainposttreatmentcancerpatients |